The Efficacy and Safety of UGN-102 as a Primary Chemoablative Therapy in Patients With LG NMIBC at Intermediate Risk of Recurrence



Status:Recruiting
Conditions:Prostate Cancer, Cancer, Cancer, Bladder Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/4/2019
Start Date:October 25, 2018
End Date:September 2020
Contact:Robert Kirshoff, MS, CNS, CCRC
Email:robert.kirshoff@urogen.com
Phone:1-646-768-0772

Use our guide to learn which trials are right for you!

A Phase 2b, Single-Arm, Multicenter Trial to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk of Recurrence

The study is investigating the efficacy and safety of UroGen's UGN-102 to treat patients with
Low Grade (LG) Non Muscle Invasive Bladder Cancer (NMIBC) at intermediate risk of recurrence.

This study is a prospective, open-label, single-arm, multicenter Phase 2b trial designed to
assess the efficacy and safety of UGN-102 treatment instilled in patients diagnosed with LG
NMIBC, including newly diagnosed patients, and determined to have intermediate risk of
progression, defined as 1 or 2 of the following: multiple tumors, tumors >3 cm, early
recurrence (within 1 year of diagnosis), or frequent recurrence (>1 recurrence within 1 year
of current diagnosis). Eligible patients will be treated with 6 weekly instillations of
UGN-102.

UGN-102 is a reverse thermal hydrogel formulated with MMC. The product is specifically
formulated to achieve a liquid state at 4°C and to transition to a water-soluble gel at body
temperature. The advantage of delivering Mitomycin to the urinary bladder using UGN-102
relies on preclinical and clinical literature documenting that concentration and dwell time
correlate directly with the therapeutic efficacy of MMC when used to treat Urothelial
Carcinoma (UC)

The ablative effect of UGN-102 will be evaluated at the Primary Disease Evaluation (3 MONTH)
assessment, which will take place 5 weeks ±1 week after the last weekly instillation (3
months after initiation of study medication). Response will be determined based on visual
evaluation by cystoscopy (appearance, number, size, and location of the lesions) and, if
there are remaining lesions, by histopathology of the remaining lesions. CR is defined as
having no detectable disease (NDD) and will be assessed visually during cystoscopy and also
upon urine cytology. In the event that the investigator is not sure, and there is suspect
tissue, a small biopsy will be taken from the suspect tissue to confirm CR in addition to
cystoscopy and urine cytology. Patients who achieve a CR will receive monthly maintenance
treatments with UGN-102 and will be assessed at 6, 9, and 12 months after the first
instillation of UGN-102 for evidence of disease recurrence. The group of patients considered
nonresponders (non-CR) will discontinue the study and continue with standard of care
according to their treating physician.

Safety will be determined based on physical examination, laboratory assessments, and a review
of AEs. All safety data will be reviewed on an ongoing basis, including close review and
follow up of any unexpected AE related to UGN-102 and qualified per National Cancer Institute
(NCI) Common Terminology Criteria for Adverse Events (CTCAE) as Grade 3 or 4.

Inclusion Criteria:

1. ≥ 18 years of age.

2. Willing and able to sign an informed consent and comply with the protocol.

3. Has newly diagnosed or historic LG NMIBC (Ta) histologically confirmed by cold cup
biopsy at screening or within 6 weeks of screening

4. Is at intermediate risk for progression, defined as having 1 or 2 of the following:

1. presence of multiple tumors,

2. solitary tumor >3 cm

3. recurrence (≥ 1 occurrence of LG NMIBC within 1 year of the current diagnosis).

5. Has negative voiding cytology for HG disease at or within 6 weeks of enrollment.

6. Willing to use 2 acceptable forms of effective contraception from enrollment through 6
months post treatment if the female partner is of childbearing potential (defined as
premenopausal women who have not been sterilized).

7. Has adequate organ and bone marrow function as determined by routine laboratory tests
as below:

Leukocytes ≥3,000/μL (≥3×109/L), Absolute neutrophil count ≥1,500/μL (≥1.5×109/L),
Platelets ≥100,000/μL (≥100×109/L), Hemoglobin ≥9.0 mg/dL, Total bilirubin ≤1.5 upper
limit of normal (ULN), AST (SGOT)/ALT (SGPT) ≤2.5 × upper limit of normal (ULN), ALP
≤2.5 × ULN, and Estimated glomerular filtration rate (eGFR) ≥30 mL/min.

8. Has no evidence of active urinary tract infection (UTI) at Screening and Baseline
visits.

In the case of symptomatic UTI, the patient will be treated with a full course of
antibiotics, and study medication will be postponed until resolution. In the case of
asymptomatic bacteriuria, the use of prophylactic antibiotics and postponement of study
medication is left to the discretion of the Principal Investigator (PI).

Exclusion Criteria:

1. History of Carcinoma in Situ (CIS) on preliminary cystoscopy within 5 years of
enrollment.

2. Received Bacillus Calmette-Guérin (BCG) treatment for UC within previous 2 years.

3. History of HG papillary UC in the past [2] years

4. Known allergy or sensitivity to mitomycin.

5. Clinically significant urethral stricture that would preclude passage of a urethral
catheter.

6. History of pelvic radiotherapy.

7. History of:

1. neurogenic bladder

2. active urinary retention

3. any other condition that would prohibit normal voiding

8. Past or current muscle invasive (i.e., T2, T3, T4) or metastatic UC or concurrent
upper tract urothelial carcinoma (UTUC).

9. Has participated in a study with an investigational agent or device within 30 days of
enrollment.

10. History of prior treatment with an intravesical chemotherapeutic agent with the
exception of a single dose of chemotherapy immediately post-TURBT.

11. Has an underlying substance abuse or psychiatric disorder such that, in the opinion of
the investigator, the patient would be unable to comply with the protocol.
We found this trial at
23
sites
New York, New York 10016
?
mi
from
New York, NY
Click here to add this to my saved trials
1200 Moursund Street
Houston, Texas 77030
(713) 798-4951
Phone: 713-798-4001
Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...
?
mi
from
Houston, TX
Click here to add this to my saved trials
101 Jessup Hall
Iowa City, Iowa 52242
(319) 335-3500
Phone: 319-356-2421
University of Iowa With just over 30,000 students, the University of Iowa is one of...
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
Phone: 734-647-8903
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
1101 East 33rd Street
Baltimore, Maryland 21287
Phone: 410-550-3506
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
Phone: 919-966-8217
Univ of North Carolina Carolina’s vibrant people and programs attest to the University’s long-standing place...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Denver, Colorado 80211
Phone: 303-762-7155
?
mi
from
Denver, CO
Click here to add this to my saved trials
Fredericksburg, Texas 78233
Phone: 210-617-4116
?
mi
from
Fredericksburg, TX
Click here to add this to my saved trials
Haifa, 34362
Phone: 972-537176389
?
mi
from
Haifa,
Click here to add this to my saved trials
Hershey, Pennsylvania 17033
Phone: 717-531-8887
?
mi
from
Hershey, PA
Click here to add this to my saved trials
Little Rock, Arkansas 72211
Phone: 501-219-8900
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Los Angeles, California 90095
Phone: 310-206-8183
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Los Angeles, California 90048
Phone: 310-854-9898
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
823 82nd Parkway, Suite B
Myrtle Beach, South Carolina 29572
(843) 449-1010 ext.268
Phone: 843-839-1679
Carolina Urologic Research Center Carolina Urologic Research Center (CURC) has been recognized both nationally and...
?
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Nashville, Tennessee 37209
Phone: 615-250-9268
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New York, New York 14225
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10021
Phone: 212-746-5788
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10461
Phone: 718-920-4531
?
mi
from
New York, NY
Click here to add this to my saved trials
Omaha, Nebraska 68114
Phone: 402-399-7894
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Phoenix, Arizona 85054
Phone: 855-776-0015
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Pompano Beach, Florida 33060
?
mi
from
Pompano Beach, FL
Click here to add this to my saved trials
2121 Santa Monica Boulevard
Santa Monica, California 90404
Phone: 520-440-5142
?
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Springfield, Oregon 97477
Phone: 541-284-5509
?
mi
from
Springfield, OR
Click here to add this to my saved trials